Researchers Find Biomarker Tied to Severity of Ulcerative Colitis
By Elana Gotkine HealthDay Reporter
FRIDAY, Oct. 18, 2024 -- For patients with ulcerative colitis, the HLA-DRB1*01:03 allele is associated with severe ulcerative colitis, according to a research letter published online Oct. 15 in the Journal of the American Medical Association to coincide with the United European Gastroenterology Week, held from Oct. 12 to 15 in Vienna.
Marie Vibeke Vestergaard, from Aalborg University in Denmark, and colleagues conducted a Danish nationwide genome-wide association study on severe versus less severe ulcerative colitis to identify biomarkers using data from a combined cohort of 4,491 patients (4,153 from the neonatal blood spot cohort [NBS] and 338 from the North Denmark Biobank study [NorDIBD]).
The researchers found that a chromosome 6 locus within the HLA region was significantly associated with severe versus less severe ulcerative colitis from 9,508,878 tested single-nucleotide variations (odds ratio, 2.23). The HLA-DRB1*01:03 allele explained this association (odds ratio, 3.32 overall; 3.29 for NBS and 3.98 for NorDIBD). No other allele had a P value below the genome-wide significance threshold. The association with the HLA-DRB1*01:03 allele had odds ratios of 6.38, 5.24, and 2.30 for major operation, at least two hospitalizations, and use of at least 5,000 mg of systemic corticosteroids for carriers versus noncarriers. For carriers versus noncarriers, the hazard ratios were 2.22, 5.13, and 1.69 for time to hospitalization, time to major operation, and time to first treatment with systemic corticosteroids, respectively.
"Given the low cost of typing a single HLA allele, HLA-DRB1*01:03 could be a valuable tool for risk assessment of patients with ulcerative colitis at diagnosis," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Guselkumab Efficacious for Moderately to Severely Active Crohn Disease in Adults
THURSDAY, July 24, 2025 -- Intravenous induction followed by subcutaneous maintenance therapy with guselkumab is efficacious for adults with moderately to severely active Crohn...
Digital Model Based on Noninvasive Factors Shows Accuracy for Identifying IBD in Children
TUESDAY, July 22, 2025 -- A model based on noninvasive tests shows high accuracy as a digital tool for the rapid identification of children with inflammatory bowel disease (IBD)...
Healthy Plant-Based Diet May Lower Inflammatory Bowel Disease Risk
WEDNESDAY, July 16, 2025 -- A healthy plant-based diet may reduce the risk for inflammatory bowel disease (IBD) due to the anti-inflammatory properties of the diet, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.